Scandinavian Journal of Urology最新文献

{"title":"A prospective randomised pilot study evaluating the safety of the novel LubriShield™ Foley catheter: a permanently coated indwelling urinary catheter.","authors":"Anders Andreasson, Jan Andersson, Henrik Larsson, Teresa Ekerhult, Johan Stranne","doi":"10.2340/sju.v60.43994","DOIUrl":"https://doi.org/10.2340/sju.v60.43994","url":null,"abstract":"<p><strong>Objective: </strong>Catheter-associated urinary tract infections (CAUTIs) are prevalent healthcare-associated infections, arising from biofilm-forming bacteria. This may be prevented by coating the catheter with an antifouling substance. The novel LubriShield™ Foley catheter is coated with a superhydrophilic surface and a covalently bonded antifouling ligand. Preclinical studies revealed that the coating established a persistent local antifouling environment, inhibiting uropathogenic bacteria from forming biofilms. No substance release has been detected from the coating. The coating achieved a 28-fold reduction in surface friction compared to an uncoated catheter. The aim of this study is to assess the clinical safety of the catheter in patients.</p><p><strong>Materials & methods: </strong>In a prospective single-centre randomised study, 30 patients undergoing transurethral resection of bladder tumour were enrolled and randomly assigned to receive either a standard control catheter or the novel LubriShield™ catheter. Urinary cultures were obtained twice. The duration of catheterisation for the patients ranged from 3 to 24 h. The primary outcome was the assessment of device-specific adverse events (AEs). Secondary outcomes included evaluations of pain, irritation and discomfort, measured using the Numeric Rating Scale (NRS) (0-10) via a patient questionnaire.</p><p><strong>Results: </strong>There were no serious adverse events (SAEs) or AEs reported for the coated catheters. Urinary cultures showed no significant differences between the coated and uncoated catheters. Both patients and healthcare professionals rated the NRS equally for the two types of catheters.</p><p><strong>Conclusions: </strong>The novel-coated LubriShield™ catheter was found to be safe for short-term clinical use.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"124-129"},"PeriodicalIF":1.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Photodynamic diagnosis (PDD) at primary TURB: Potential influence on recurrence and progression rates in NMIBC: a registry-based study using a country cohort.","authors":"Linea Blichert-Refsgaard, Maria S Lindgren, Maria Ordell Sundelin, Charlotte Graugaard-Jensen, Mette Nørgaard, Jørgen Bjerggaard Jensen","doi":"10.2340/sju.v60.43993","DOIUrl":"https://doi.org/10.2340/sju.v60.43993","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether department-level use of photodynamic diagnosis (PDD) for primary transurethral bladder resections (TURBs) is associated with recurrence and progression rates in a non-selected, national cohort. Non-muscle invasive bladder cancer (NMIBC) has high global prevalence, and is characterized by high recurrence risk and risk of progression to muscle-invasive bladder cancer. Treatment effects and long-term outcomes rely on diagnostic accuracy, which may be enhanced using PDD for TURB. PDD-use in Denmark has varied between departments.  Material and Methods: We identified all Danish patients with primary NMIBC during 2011-2017 via the Danish National Patient Registry (DNPR) and divided them into four groups based on the treating department's annual PDD use. We included 8,502 patients; 76% men, median age at diagnosis: 70 years (interquartile range [IQR]: 63, 77). Primary outcomes were recurrence- and progression risk differences (RDs) at 2 and 5 years depending on the PDD-exposure group. Results were additionally stratified by baseline pathological risk group.</p><p><strong>Results: </strong>The PDD-use varied from <40% of primary TURBs in group 1 to >74% in group 4. Overall 2- and 5 years recurrence risks were 39.9% [95% CI: 38.8; 41.0] and 48.1% [95% CI: 46.9; 49.3], while risks of progression were 17.5% [95% CI: 16.7; 18.4] and 22.9% [95% CI: 21.9; 23.9]. PDD-exposure groups 2-4 had lower recurrence- and progression risks compared to group 1, most pronounced for high-risk NMIBC.</p><p><strong>Conclusions: </strong>PDD-use in primary TURBs correlates with reduced 2- and 5 years recurrence- and progression risks in NMIBC. The PDD benefit was most noticeable in higher risk NMIBC. Photodynamic diagnosis, primary Trans Urethral Resection of the Bladder (TURB), progression risk, recurrence risk.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"115-123"},"PeriodicalIF":1.4,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of treatment patterns and outcomes in muscle-invasive bladder cancer patients in Sweden.","authors":"Kelvin H M Kwok, Ahmad Abbadi, Sarah Côté, Simona Baculea, Samuel Spigelman, Markus Aly, Frida Schain","doi":"10.2340/sju.v60.43875","DOIUrl":"https://doi.org/10.2340/sju.v60.43875","url":null,"abstract":"<p><strong>Objective: </strong>For patients diagnosed with muscle-invasive bladder cancer (MIBC), prognosis remains poor with high rates of progression and risk for mortality. To better understand the current treatment landscape, this study aims to describe real-world treatment patterns and clinical outcomes for MIBC patients in Sweden.</p><p><strong>Materials and methods: </strong>Using population-based registers and electronic medical records, patients with MIBC (T2-4aN0M0) were identified between January 2016 and December 2020 in the Skåne region in Sweden. Patients with de novo MIBC and those who progressed from high-risk nonmuscle-invasive bladder cancer were included. Treatment patterns, overall survival (OS), metastatic rate, event-free survival (EFS), and bladder-intact EFS (BI-EFS) were described.  Results: Among the 231 MIBC patients identified, 34% received only best supportive care (BSC) primarily due to age and comorbidity. Of the 153 patients who received curative treatment, 84 (55%) underwent radical cystectomy (RC) and 69 (45%) received bladder-sparing treatment. Patients who received bladder-sparing treatment were older, had poorer health status, and more comorbidities. Among RC-treated patients, 5-year OS and EFS were 74% (95% confidence interval [CI]: 61-83%) and 70% (95% CI: 58-79%), respectively. Among patients who received bladder-sparing treatment, 5-year OS and BI-EFS were 52% (95% CI: 38-64%) and 34% (95% CI: 21-48%), respectively.</p><p><strong>Conclusions: </strong>Old age and high rates of comorbidities among the MIBC patient population meant many patients were ineligible for recommended RC and instead received bladder-sparing treatment or BSC only. High rates of progression and poor survival were observed in both patients undergoing RC and patients who received bladder-sparing treatment.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"108-114"},"PeriodicalIF":1.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of comorbidity indices and estimates of life expectancy for men with prostate cancer.","authors":"Eugenio Ventimiglia, Rolf Gedeborg, Andri Wilberg Orrason, Paolo Zaurito, Hans Garmo, Pär Stattin, Marcus Westerberg","doi":"10.2340/sju.v60.43810","DOIUrl":"https://doi.org/10.2340/sju.v60.43810","url":null,"abstract":"<p><p>N/A.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"105-107"},"PeriodicalIF":1.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swedish regional population-based organised prostate cancer testing: why, what and how?","authors":"Ola Bratt, Salma Tunå Butt, Charlotte Carlsson, Lisa Jelf-Eneqvist, Olof Gunnarsson, Alma Ihre, Thomas Jiborn, Anna Lantz, Heide Larsson, Helena Strömqvist, Johan Styrke, Nils-Erik Svedberg, Rebecka Arnsrud Godtman","doi":"10.2340/sju.v60.43809","DOIUrl":"https://doi.org/10.2340/sju.v60.43809","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to describe the regional, population-based, organised prostate cancer testing (OPT) programmes that are being introduced throughout Sweden: motives, structure, target population, diagnostic algorithm, quality control, outcomes, research, and future perspectives.</p><p><strong>Results: </strong>In 2018, the Swedish National Board of Health and Welfare renewed their recommendation against screening for prostate cancer. Despite this, regional OPT was considered motivated to (1) improve cost-effectiveness compared with unorganised testing, (2) improve equity by giving every man in the target population a chance to make an informed choice, and (3) gain diagnostic and organisational knowledge. The OPT programmes are provided as a regional public healthcare service. They are coordinated by a national working group. The final target population is all men aged 50-74 years. Regional OPT offices use a national administrative system to organise all steps from sending invitation letters to prostate biopsy according to a strict diagnostic algorithm. General practice is involved for blood draw only or not at all. Data are registered in a national register (SweOPT); an annual report is published with the regions' performance on key indicators. At the end of 2024, 16 of the 21 Swedish regions had started OPT and invited 256,000 men with an average cumulative participation rate of 43%. A consortium co-ordinates OPT-related research. A general experience is that communication and organisational matters have been more challenging than medical decisions.</p><p><strong>Conclusions: </strong>The Swedish population-based OPT programmes provide organisational experiences, diagnostic outcomes, and research results of value for future national prostate cancer screening programmes.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"97-104"},"PeriodicalIF":1.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer incidence in Sweden before, during and after the COVID-19 pandemic. Population-based study.","authors":"Paolo Zaurito, Hans Garmo, Rolf Gedeborg, Mats Ahlberg, Andri Wilberg Orrason, Johan Styrke, David Robinson, Pär Stattin, Marcus Westerberg","doi":"10.2340/sju.v60.43172","DOIUrl":"https://doi.org/10.2340/sju.v60.43172","url":null,"abstract":"<p><p>N/A.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"93-96"},"PeriodicalIF":1.4,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inferior vena cava syndrome as the initial manifestation of metastatic prostate cancer: a rare case successfully treated with endovascular stenting.","authors":"Dimitra Akrivou, Andreas Forsvall, Angelos Katevatis, Tobias Kühme, Anna Eliasson, Magnus Wagenius","doi":"10.2340/sju.v60.43708","DOIUrl":"https://doi.org/10.2340/sju.v60.43708","url":null,"abstract":"","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"90-92"},"PeriodicalIF":1.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early and late surgical complications following living donor nephrectomy.","authors":"Julia Dagnæs-Hansen, Gitte H Kristensen, Malene Rohrsted, Søren S Sørensen, Andreas Røder","doi":"10.2340/sju.v60.43346","DOIUrl":"https://doi.org/10.2340/sju.v60.43346","url":null,"abstract":"<p><strong>Objective: </strong>To report early and late surgical complications following laparoscopic, open and hand-assisted laparoscopic living donor nephrectomy, including duration of sick leave, kidney function and potential risk factors for surgical complications.</p><p><strong>Material and methods: </strong>Retrospective study on living kidney donors between September 2014 and June 2021 at Rigshopitalet, Copenhagen. Patient data included demographics, comorbidities, surgical information, and postoperative complications (early <30 days and late >30 days). Complications were graded according to Clavien Dindo (CD). Return to work and reasons for prolonged sick leave were recorded. Multivariable logistic regression to identify risk factors for early complications CD ≥ 2 and time-dependent cause specific Cox regression to identify risk factors for late complications.  Results: A total of 223 living donors were included. Early complications were observed in 22% of donors. Early complications were often mild, and the most common complications were pneumonia, wound infection, and urinary retention. Of the 201 donors available for long-term follow-up, 10% experienced a late complication, including incisional port-site hernia and chronic post-surgical pain. 18% reported a prolonged sick leave beyond the planned 6 weeks.  Conclusions: Living donor nephrectomy is associated with a low risk of serious early surgical complications although many will experience minor related complications. As surgical safety has been confirmed in several studies the focus should be on the psychoscial and long-term aspects of living kidney donation to meet donor concerns pre-donation.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"83-89"},"PeriodicalIF":1.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease.","authors":"Anders Ullén, Firas Aljabery, Pär Dahlman, Karin Falkman, Truls Gårdmark, Tomas Jerlström, Susanna Holst, Sofia Kjellström, Anna-Karin Lind, Dimitrios Papantoniou, Jonas Stenlund, Viveka Ströck, Karin Söderkvist, Helena Thulin, Elin Trägårdh, Ingrida Verbiene, Jonas Wallström, Elisabeth Öfverholm, Fredrik Liedberg","doi":"10.2340/sju.v60.43236","DOIUrl":"10.2340/sju.v60.43236","url":null,"abstract":"<p><strong>Objective: </strong>To overview and summarise the Swedish National Guidelines on Urothelial Carcinoma 2024.</p><p><strong>Methods: </strong>A narrative review of the updated guidelines was performed, highlighting new treatment recommendations for advanced and metastasized disease.  Results: Compared to the previous guideline version, the current update includes recommendations for standardised radiological reporting when urothelial carcinomas are detected at CT-urography (CTU), to early identify locally advanced patients and accelerate the care pathway for these patients. The Swedish guidelines apply a more structured and liberal recommendation for the use of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with locally advanced urothelial carcinomas compared to the EAU-guidelines and recommend such examinations prior to transurethral resection. Improved outcomes for radical cystectomy in Sweden after centralised cystectomy care have led to a recommendation for performing more than six nephroureterectomies (NUs) per year for upper tract urothelial carcinomas (UTUC)-based associations with decreased use of invasive diagnostic modalities and better survival outcomes. Additionally, updated recommendations regarding adjuvant systemic therapies for muscle-invasive disease have been included. Whilst awaiting national regulatory approval for enfortumab vedotin/pembrolizumab, the present guideline version aligns with EAU-guidelines by endorsing cisplatin-gemcitabine-nivolumab as a new first-line treatment option in cisplatin-fit patients with unresectable or metastatic urothelial carcinoma.</p><p><strong>Conclusions: </strong>The current version of the Swedish national guidelines on urothelial carcinoma introduces standardised reporting at CTU to facilitate early identification of advanced disease, includes recommendations for centralisation of NU for UTUC and updated recommendations for adjuvant systemic treatment of muscle-invasive disease and endorses cisplatin-gemcitabine-nivolumab as a new first-line treatment option for non-resectable locally advanced and metastatic disease.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"76-82"},"PeriodicalIF":1.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected Liver Metastasis Three Years after Nephrectomy for Renal Oncocytoma: A Case-report and Review of Literature.","authors":"Pekka Lammi, Anna Junttila, Essi Ikonen, Arto Salonen, Olli Lahtinen, Antti Kivivuori","doi":"10.2340/sju.v60.43205","DOIUrl":"10.2340/sju.v60.43205","url":null,"abstract":"<p><p>N/A.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":"60 ","pages":"73-75"},"PeriodicalIF":1.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}